The US Food and Drug Administration (FDA) has approved AstraZeneca's Farxiga (dapagliflozin) for improving glycaemic control in children with type-2 diabetes (T2D) aged 10 and older. The positive outcomes of the paediatric T2NOW phase III trial...
Suven Pharmaceuticals, which is backed by PE company Advent International, said that it has reached a definitive agreement to acquire a controlling stake in Hyderabad-based contract research development organization (CDMO) Sapala Organic for...
Cumulus Neuroscience, a worldwide digital health company dedicated to improving data for neuroscience clinical trials and patient care, has announced a collaboration with the Digital Health Measurement Collaborative Community (DATAcc) of the...
NewAmsterdam Pharma Organization N.V., a clinical biopharmaceutical organization creating oral, non-statin prescriptions for patients at risk of cardiovascular disease (CVD) with raised low-density lipoprotein cholesterol (LDL-C), for whom...
Dr Reddy's Laboratories Ltd, an India-based multinational pharmaceutical company, has entered into a licensing agreement with US-based Ingenus Pharmaceuticals, LLC to market cyclophosphamide injection, which is used to treat cancer...
Ipsen announced that Iqirvo (elafibranor) 80 mg tablets have received accelerated approval from the US Food and Drug Administration (FDA) to treat primary biliary cholangitis (PBC) in adults who do not respond well to ursodeoxycholic acid (UDCA)...
Glenmark Specialty SA (Glenmark) has received final approval by the United States Food & Drug Administration (FDA) for esomeprazole magnesium delayed-release capsules USP, 20 mg (OTC), determined by the FDA to be bioequivalent to Nexium 24 HR...
Akums Drugs & Pharmaceuticals Ltd declared the launch of Rabeprazole + Levosulpiride SR capsules. This new formulation, which was approved by the Drug Controller General of India (DCGI), aims to provide patients with better relief from disorders...
Essential Pharma, an international specialty pharmaceutical group dedicated to guaranteeing patients' long-term availability of low volume, clinically differentiated, niche pharmaceutical products across key therapeutic fields, declared that its...
Chugai Pharmaceutical Co, a drug manufacturer declared that the European Commission has sanctioned a Chugai originated anaplastic lymphoma kinase (ALK) inhibitor Alecensa monotherapy, as adjuvant treatment following growth resection for grown-up...
, CDSCO.jpg "Fostering a Quality Culture in the Pharmaceutical Industry")
